Cargando…
Future of antivirals in COVID-19: The case of favipiravir
Autores principales: | Kow, Chia Siang, Ramachandram, Dinesh Sangarran, Hasan, Syed Shahzad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666323/ https://www.ncbi.nlm.nih.gov/pubmed/34959188 http://dx.doi.org/10.1016/j.intimp.2021.108455 |
Ejemplares similares
-
Favipiravir and hyperuricemia in patients with COVID-19—suggestions for future studies
por: Kow, Chia Siang, et al.
Publicado: (2023) -
Hypertension and severe COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2023) -
Colchicine for COVID-19: Hype or hope?
por: Kow, Chia Siang, et al.
Publicado: (2022) -
Probiotics for the Prevention of COVID-19 Sequelae
por: KOW, CHIA SIANG, et al.
Publicado: (2022) -
Can COVID-19 vaccines improve cardiovascular outcomes?
por: Kow, Chia Siang, et al.
Publicado: (2022)